Key result
Enoxaparin reduces venous thromboembolism in acutely ill medical inpatients with thrombosis risk factors.
Why the study?
Does enoxaparin reduce the incidence of VTE in acutely ill inpatients with risk factors for thrombosis?
Does enoxaparin reduce the incidence of VTE in acutely ill inpatients with risk factors for thrombosis?
Enoxaparin is effective for preventing venous thromboembolism in acutely ill inpatients with thrombosis risk factors.
Answers are grounded in this paper and cite their sources.
Supports enoxaparin prophylaxis in high-risk medical inpatients; confirms VTE reduction in this RCT.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Axon et al. (2010) studied this question. Enoxaparin reduced the incidence of venous thromboembolism in acutely ill inpatients with risk factors for thrombosis.
Synapse has enriched 10 related papers. Consider them for comparative context: